TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06966401: A Long-Term, Open-Label Study to Assess the Safety and Tolerability of NBI-1065845 as Adjunctive Treatment in Subjects With Major Depressive Disorder (MDD)

Sponsor: Neurocrine Biosciences · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 850 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$10,937,408

Rescue Site Savings

+$7,213,032

Unlock Full NCT06966401 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06966401 Rescue Dossier →